NasdaqCM - Delayed Quote • USD
Titan Pharmaceuticals, Inc. (TTNP)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:03 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | -- | -- | -- | 7.05M |
| Low Estimate | -- | -- | -- | 7.05M |
| High Estimate | -- | -- | -- | 7.05M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | -0.76 | -0.43 |
| 30 Days Ago | 0 | 0 | -0.76 | -0.43 |
| 60 Days Ago | 0 | 0 | -0.76 | -0.43 |
| 90 Days Ago | 0 | 0 | -0.76 | -0.43 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | TTNP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 1.60% |
| Next Qtr. | -- | -- | -- | 10.50% |
| Current Year | -- | -- | -- | 5.20% |
| Next Year | -- | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Related Tickers
KTTA Pasithea Therapeutics Corp.
7.11
-0.14%
PRTC PureTech Health plc
26.15
-0.46%
CYCN Cyclerion Therapeutics, Inc.
3.5000
+5.58%
SABS SAB Biotherapeutics, Inc.
4.2900
-2.72%
VRPX Virpax Pharmaceuticals, Inc.
3.6801
-5.88%
MORF Morphic Holding, Inc.
27.99
+1.74%
VCNX Vaccinex, Inc.
4.8600
+3.40%
ESLA Estrella Immunopharma, Inc.
1.0700
+4.90%
FRES Fresh2 Group Limited
0.3683
+10.07%
PYPD PolyPid Ltd.
4.4000
-2.00%